Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PHYRAGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PHYRAGO.
HISTAFED vs PHYRAGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
PHYRAGO is a monoclonal antibody that targets and neutralizes the activity of a specific inflammatory cytokine, thereby inhibiting downstream signaling pathways involved in immune-mediated inflammation.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
200 mg orally twice daily with food.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is 6–8 hours in adults; may be prolonged in hepatic impairment (up to 15 hours).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <5% of dose; fecal elimination of metabolites accounts for ~90%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine